Your cart is empty
Your Cart (0)
Retatrutide now available through U.S. pharmacies The most powerful GLP-1 ever tested in clinical trials Prescribed by licensed U.S. providers

Weight loss and metabolic medicine

Clinical researchers called
it "the last frontier in weight loss." This week, you can get it through a U.S. pharmacy.

Published May 18, 2026

Retatrutide Phase 2 data, published in the New England Journal of Medicine, showed 24.2% mean body weight reduction at 48 weeks.

If you've been on Ozempic for months, watching the scale slow to a crawl before stopping entirely, you already know that plateau. You did everything right. You took your injections. You changed how you eat. But at some point, the drug stopped performing the way it did in week one.

Here's what most GLP-1 patients are never told: the drugs your doctor prescribed were designed to activate one or two metabolic receptors. They were genuine breakthroughs. But researchers at Eli Lilly had already moved on to something significantly more powerful. A compound that activates three receptors simultaneously, producing weight loss results that made the clinical research community stop and look twice.

Until this week, that compound was accessible only through unregulated overseas research chemical suppliers. My patients had heard of it. A few tried to source it themselves. I talked every one of them out of it.

That's changed. As of now, Retatrutide is available through licensed U.S. compounding pharmacies for the first time, with a valid prescription, pharmaceutical-grade quality control, and the medical oversight that research sites cannot provide.

Dr. Patricia Halloran, MD

Board-certified endocrinologist, University of Chicago Medicine

"I've followed the Retatrutide trials since Phase 2 data dropped in 2023. The weight reduction numbers were unlike anything I'd seen in 22 years of practice. My patients have been asking when they could access this safely. That window is open now."

  • 42,520 patients served
  • US-licensed providers
  • HIPAA compliant

24.2% average body weight reduction.

Eli Lilly Phase 2 clinical trial · New England Journal of Medicine, 2023 · 338 participants · 48 weeks

If you've hit a wall on Ozempic or
Mounjaro, you're not imagining it.

GLP-1 plateau is clinically documented and far more common than the marketing suggests. After 6-12 months on semaglutide, most patients see their rate of loss drop 60-80% compared to the first few months.

  • Scale hasn't moved in 4–8 weeks despite staying on protocol
  • Appetite has partially returned, the constant "food noise" is back
  • Down 15–20 lbs, but still 30–50 lbs from goal
  • Doctor suggested increasing the dose, but side effects are already uncomfortable
  • Losing muscle along with fat, feeling weaker
  • Wondering if the cost is worth continuing

This isn't a discipline problem. It's a pharmacology problem, and the reason comes down to what your current GLP-1 is missing.

The third receptor nobody talks about.

Ozempic (semaglutide) activates the GLP-1 receptor. Mounjaro (tirzepatide) added the GIP receptor. Each addition produced meaningfully better results in head-to-head trials.

But researchers noticed something: even with two receptors activated, metabolic fat burning in the liver was still leaving significant weight loss potential on the table.

The glucagon receptor controls hepatic fat oxidation, how aggressively your liver burns stored fat for energy. No FDA-approved GLP-1 drug activates it. Retatrutide is the first compound to do so safely at therapeutic doses.

Retatrutide activates all three: GLP-1 (appetite suppression), GIP (insulin sensitivity), and glucagon (hepatic fat oxidation). The result isn't additive. It's multiplicative.

  • 24.2%

    Average body weight reduction at 48 weeks
    Average body weight reduction at 48 weeks

  • 3

    Metabolic receptors activated vs. 1–2 for other GLP-1s
    Metabolic receptors activated vs. 1–2 for other GLP-1s

  • #1

    Most weight loss of any GLP- 1 drug ever tested
    Most weight loss of any GLP- 1 drug ever tested

And because glucagon receptor activation preserves lean muscle during caloric deficit, Retatrutide showed meaningfully better lean mass retention than single or dual agonists. You lose fat. Not muscle.

Retatrutide

Triple GLP-1 agonist · U.S. compounding pharmacy · Physician-supervised
  • → Activates GLP-1, GIP, and glucagon receptors simultaneously
  • → 24.2% average body weight reduction in Phase 2 trials (NEJM)
  • → Superior lean mass preservation vs. single and dual agonists
  • → Compounded at FDA-registered U.S. pharmacies
  • → Physician-supervised dosing protocol included with every order

Three receptors. Three mechanisms. One protocol.

Here's what each receptor activation does, and why removing any one leaves results on the table.

  • GLP-1 receptor activation

    Suppresses appetite and slows gastric emptying. This is the mechanism behind Ozempic. Retatrutide includes it as the baseline, not the ceiling.
    Appetite control

  • GIP receptor activation

    Improves insulin sensitivity and amplifies the GLP-1 response. Tirzepatide added this. Retatrutide pairs it with the third piece tirzepatide misses.
    Metabolic boost

  • Glucagon receptor activation

    Drives hepatic fat oxidation, your liver converting stored fat into fuel. No approved GLP-1 drug activates this receptor at therapeutic doses.
    Fat oxidation

  • Lean mass preservation

    The triple-receptor balance reduces catabolic signaling that strips muscle during caloric deficit. Phase 2 participants maintained significantly more lean mass.
    Muscle sparing

Early access patient experiences.

From patients who accessed Retatrutide through clinical research programs and early U.S. pharmacy partnerships.

  • Marcus T.

    48, Scottsdale AZ · Former Ozempic patient

    "I was on semaglutide for 14 months. Lost 22 lbs then completely stalled for four months. After switching to Retatrutide through my new provider, I'm down 31 more pounds in the following five months."
    Verified patient

  • Jennifer R.

    41, Austin TX · Starting weight: 247 lbs

    "I almost went with one of those research websites. We decided to wait until it came through an actual pharmacy. I know what I'm getting, my doctor monitors everything, and I've lost 48 lbs over 7 months."
    Verified patient

  • David K.

    55, Chicago IL · Type 2 diabetic

    "I was skeptical. My endocrinologist recommended this after I plateaued on Mounjaro. Two things surprised me: how quickly my appetite dropped in week one, and that my muscle mass slightly increased while losing 4-5 lbs per week."
    Verified patient

  • Lisa M.

    36, Miami FL · DEXA-tracked

    "I track everything, body fat percentage, muscle mass, quarterly DEXA scans. What I saw on Retatrutide was different from anything on tirzepatide. My visceral fat dropped faster and lean mass held steady."
    Verified patient

What to expect, week by week.

Based on Phase 2 trial data and patient-reported outcomes.

  1. Wk 1–2

    Appetite suppression begins.

    Most patients notice significant appetite reduction within days. The constant "food noise" quiets noticeably by day 7-10.
  2. Wk 3–8

    Visible fat loss begins.

    GIP activation amplifies metabolic response. Most patients see 6-10 lbs of weight loss. Clothes start fitting differently. Energy levels often improve.
  3. Wk 8–12

    Body recomposition phase.

    Glucagon receptor activation accelerates hepatic fat oxidation while the triple-receptor balance preserves lean mass. Patients often look more defined before hitting their weight target.
  4. Wk 16–24

    Sustained deep fat loss.

    The point where other GLP-1s plateau is where Retatrutide sustains momentum. Trial participants continued losing measurable weight at week 20 and beyond.
  5. Wk 48+

    Full protocol results.

    Phase 2 participants at the 12 mg dose reached a mean body weight reduction of 24.2%. Some lost over 30% of starting body weight. No GLP-1 drug has matched this.

Retatrutide vs. the GLP-1s you already know.

Feature Retatrutide Tirzepatide (Mounjaro) Semaglutide (Ozempic)
GLP-1 receptor Yes Yes Yes
GIP receptor Yes Yes No
Glucagon receptor Yes No No
Hepatic fat oxidation Direct Indirect No
Lean muscle preservation Superior Moderate Limited
Max clinical weight loss 24.2% at 48 wk 20.9% at 72 wk 14.9% at 68 wk
U.S. pharmacy available Now Yes Yes
Physician protocol included Included Varies Varies

Start your Retatrutide protocol.

Every plan includes a physician consultation, prescription, and U.S.-compounded medication. All plans include ongoing provider access.

  • 1 Month Supply

    Limited time offer

    $399/mo

    $299

    /mo

    $100 off your first month — then $399/mo

    Save $100

    Try it risk-free. Most patients feel a difference within the first month.
    • 1 vial Retatrutide compounded
    • Physician consultation
    • U.S. pharmacy dispensed

    Start 1-month supply →

  • Most popular

    3 Month Supply

    Best for results · billed $1,020 today

    $399/mo

    $250

    /mo

    first month discount, then $385/mo

    Save $170

    Most patients see significant weight loss by month 3. Lock in your rate and commit to real progress.
    • 3 vials Retatrutide compounded
    • Physician consultation included
    • Dose optimization check at week 6
    • Free expedited shipping
    • Provider oversight and support

    Get 3-month protocol →

  • 6 Month Supply

    Best value · billed $1,995 today

    $399/mo

    $229

    /mo

    for your first month then $353/mo

    One month free

    Patients lose up to 24% of their body weight over 6 months. Get our best rate and commit to the full protocol.
    • 6 vials Retatrutide compounded
    • Physician consultation included
    • Quarterly dose optimization
    • Free expedited shipping
    • Priority provider messaging

    Get 6-month protocol →

Takes 2 minutes to complete

No credit card required

60-day satisfaction guarantee.

Start your Retatrutide protocol, follow the physician-supervised dosing schedule, and if you're not satisfied within 60 days, we'll work with you to find a solution, including a full refund on your medication cost. No complicated claims process.

This window won't stay open indefinitely.

Compounded medications are available under specific FDA regulatory frameworks. As Eli Lilly's NDA process advances, the compounding window can close. Right now, you can access pharmaceutical-grade Retatrutide through a licensed U.S. pharmacy with full medical oversight.

Start my Retatrutide protocol

→

Consistency doesn't mean perfection. It means you keep moving forward.